420 related articles for article (PubMed ID: 28423611)
1. The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
Sullivan KE; Rojas K; Cerione RA; Nakano I; Wilson KF
Oncotarget; 2017 Apr; 8(14):22325-22343. PubMed ID: 28423611
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3.
Mao P; Joshi K; Li J; Kim SH; Li P; Santana-Santos L; Luthra S; Chandran UR; Benos PV; Smith L; Wang M; Hu B; Cheng SY; Sobol RW; Nakano I
Proc Natl Acad Sci U S A; 2013 May; 110(21):8644-9. PubMed ID: 23650391
[TBL] [Abstract][Full Text] [Related]
3. USP9X deubiquitinates ALDH1A3 and maintains mesenchymal identity in glioblastoma stem cells.
Chen Z; Wang HW; Wang S; Fan L; Feng S; Cai X; Peng C; Wu X; Lu J; Chen D; Chen Y; Wu W; Lu D; Liu N; You Y; Wang H
J Clin Invest; 2019 Apr; 129(5):2043-2055. PubMed ID: 30958800
[TBL] [Abstract][Full Text] [Related]
4. ALDH1A3: A Marker of Mesenchymal Phenotype in Gliomas Associated with Cell Invasion.
Zhang W; Liu Y; Hu H; Huang H; Bao Z; Yang P; Wang Y; You G; Yan W; Jiang T; Wang J; Zhang W
PLoS One; 2015; 10(11):e0142856. PubMed ID: 26575197
[TBL] [Abstract][Full Text] [Related]
5. ALDH1A3 in CSCs.
Sullivan KE; Cerione RA; Wilson KF
Aging (Albany NY); 2017 May; 9(5):1351-1352. PubMed ID: 28476022
[No Abstract] [Full Text] [Related]
6. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
7. FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells.
Cheng P; Wang J; Waghmare I; Sartini S; Coviello V; Zhang Z; Kim SH; Mohyeldin A; Pavlyukov MS; Minata M; Valentim CL; Chhipa RR; Bhat KP; Dasgupta B; La Motta C; Kango-Singh M; Nakano I
Cancer Res; 2016 Dec; 76(24):7219-7230. PubMed ID: 27569208
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells.
Chandran UR; Luthra S; Santana-Santos L; Mao P; Kim SH; Minata M; Li J; Benos PV; DeWang M; Hu B; Cheng SY; Nakano I; Sobol RW
Genom Data; 2015 Sep; 5():333-336. PubMed ID: 26251826
[TBL] [Abstract][Full Text] [Related]
9. Stem cell signature in glioblastoma: therapeutic development for a moving target.
Nakano I
J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
[TBL] [Abstract][Full Text] [Related]
10. A specific inhibitor of ALDH1A3 regulates retinoic acid biosynthesis in glioma stem cells.
Li J; Garavaglia S; Ye Z; Moretti A; Belyaeva OV; Beiser A; Ibrahim M; Wilk A; McClellan S; Klyuyeva AV; Goggans KR; Kedishvili NY; Salter EA; Wierzbicki A; Migaud ME; Mullett SJ; Yates NA; Camacho CJ; Rizzi M; Sobol RW
Commun Biol; 2021 Dec; 4(1):1420. PubMed ID: 34934174
[TBL] [Abstract][Full Text] [Related]
11. Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells.
Wu W; Schecker J; Würstle S; Schneider F; Schönfelder M; Schlegel J
Cancer Lett; 2018 Mar; 417():112-123. PubMed ID: 29306018
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBPβ Signaling.
Yin J; Oh YT; Kim JY; Kim SS; Choi E; Kim TH; Hong JH; Chang N; Cho HJ; Sa JK; Kim JC; Kwon HJ; Park S; Lin W; Nakano I; Gwak HS; Yoo H; Lee SH; Lee J; Kim JH; Kim SY; Nam DH; Park MJ; Park JB
Cancer Res; 2017 Sep; 77(18):4973-4984. PubMed ID: 28754668
[TBL] [Abstract][Full Text] [Related]
13. Cell surface GRP78 regulates BACE2 via lysosome-dependent manner to maintain mesenchymal phenotype of glioma stem cells.
Chen Z; Wang H; Zhang Z; Xu J; Qi Y; Xue H; Gao Z; Zhao R; Wang S; Zhang S; Qiu W; Guo X; Li G
J Exp Clin Cancer Res; 2021 Jan; 40(1):20. PubMed ID: 33413577
[TBL] [Abstract][Full Text] [Related]
14. High expression of ALDH1A3 might independently influence poor progression-free and overall survival in patients with glioma via maintaining glucose uptake and lactate production.
Ni W; Xia Y; Luo L; Wen F; Hu D; Bi Y; Qi J
Cell Biol Int; 2020 Feb; 44(2):569-582. PubMed ID: 31642564
[TBL] [Abstract][Full Text] [Related]
15. Deubiquitinating ALDH1A3 key to maintaining the culprit of aggressive brain cancer.
Wakimoto H
J Clin Invest; 2019 Apr; 129(5):1833-1835. PubMed ID: 30958802
[TBL] [Abstract][Full Text] [Related]
16. ALDH1A3, a metabolic target for cancer diagnosis and therapy.
Duan JJ; Cai J; Guo YF; Bian XW; Yu SC
Int J Cancer; 2016 Sep; 139(5):965-75. PubMed ID: 26991532
[TBL] [Abstract][Full Text] [Related]
17. Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3.
Thomas ML; de Antueno R; Coyle KM; Sultan M; Cruickshank BM; Giacomantonio MA; Giacomantonio CA; Duncan R; Marcato P
Mol Oncol; 2016 Nov; 10(9):1485-1496. PubMed ID: 27592281
[TBL] [Abstract][Full Text] [Related]
18. Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling.
Marcato P; Dean CA; Liu RZ; Coyle KM; Bydoun M; Wallace M; Clements D; Turner C; Mathenge EG; Gujar SA; Giacomantonio CA; Mackey JR; Godbout R; Lee PW
Mol Oncol; 2015 Jan; 9(1):17-31. PubMed ID: 25106087
[TBL] [Abstract][Full Text] [Related]
19. TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells.
Fu J; Yang QY; Sai K; Chen FR; Pang JC; Ng HK; Kwan AL; Chen ZP
Neuro Oncol; 2013 Oct; 15(10):1353-65. PubMed ID: 23877317
[TBL] [Abstract][Full Text] [Related]
20. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
